Organon & Co. financial data

Symbol
OGN on NYSE
Industry
Pharmaceutical Preparations
Location
30 Hudson Street, Fl 33, Jersey City, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 163 % +1.1%
Quick Ratio 47.7 % +2.94%
Debt-to-equity 7.84K %
Return On Equity 846 %
Return On Assets 10.7 % +99%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 258M shares +0.76%
Common Stock, Shares, Outstanding 258M shares +0.76%
Entity Public Float 5.3B USD -38.4%
Common Stock, Value, Issued 3M USD 0%
Weighted Average Number of Shares Outstanding, Basic 257M shares +0.75%
Weighted Average Number of Shares Outstanding, Diluted 260M shares +1.33%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 6.41B USD +4.21%
Research and Development Expense 472M USD +103%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 782M USD +15%
Income Tax Expense (Benefit) -519M USD -646%
Net Income (Loss) Attributable to Parent 1.3B USD +122%
Earnings Per Share, Basic 5.06 USD/shares +119%
Earnings Per Share, Diluted 5.03 USD/shares +120%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 763M USD +84.3%
Accounts Receivable, after Allowance for Credit Loss, Current 1.69B USD +2.25%
Inventory, Net 1.38B USD +16.6%
Other Assets, Current 925M USD +15.3%
Assets, Current 4.76B USD +17.4%
Property, Plant and Equipment, Net 1.2B USD +9.85%
Operating Lease, Right-of-Use Asset 173M USD -19.5%
Goodwill 4.6B USD 0%
Assets 12.8B USD +15.8%
Accounts Payable, Current 1.09B USD +2.34%
Liabilities, Current 2.79B USD +12%
Deferred Income Tax Liabilities, Net 56M USD +30.2%
Operating Lease, Liability, Noncurrent 125M USD -16.7%
Other Liabilities, Noncurrent 674M USD +60.1%
Liabilities 12.3B USD +5.67%
Accumulated Other Comprehensive Income (Loss), Net of Tax -571M USD +0.87%
Retained Earnings (Accumulated Deficit) 975M USD
Stockholders' Equity Attributable to Parent 493M USD
Liabilities and Equity 12.8B USD +15.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 76M USD -33.3%
Net Cash Provided by (Used in) Financing Activities -74M USD +77.3%
Net Cash Provided by (Used in) Investing Activities -96M USD -77.8%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 258M shares +0.76%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -118M USD +52.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 763M USD +84.3%
Deferred Tax Assets, Valuation Allowance 309M USD +494%
Deferred Tax Assets, Gross 1.17B USD +174%
Operating Lease, Liability 171M USD -14.1%
Depreciation 32M USD +14.3%
Payments to Acquire Property, Plant, and Equipment 46M USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.31B USD +87.9%
Lessee, Operating Lease, Liability, to be Paid 189M USD -14.1%
Operating Lease, Liability, Current 46M USD -6.12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 48M USD -2.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 52M USD -7.14%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +25%
Deferred Income Tax Expense (Benefit) 5M USD +66.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18M USD -14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 29M USD -37%
Deferred Tax Assets, Operating Loss Carryforwards 35M USD -46.2%
Unrecognized Tax Benefits 115M USD +23.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14M USD -22.2%
Deferred Tax Assets, Net of Valuation Allowance 863M USD +130%
Share-based Payment Arrangement, Expense 106M USD +9.28%
Interest Expense 517M USD 0%